Application of Imaging Technologies in Breast Cancer Detection: A Review Article

Overview

Journal Open Access Maced J Med Sci

Specialty General Medicine

Date 2019 Apr 10

PMID 30962849

Citations 19

Authors

Zeinab Safarpour Lima

Mohammad Reza Ebadi

Ghazaleh Amjad

Ladan Younesi

Affiliations

Soon will be listed here.

Abstract

One of the techniques utilised in the management of cancer in all stages is multiple biomedical imaging. Imaging as an important part of cancer clinical protocols can provide a variety of information about morphology, structure, metabolism and functions. Application of imaging technics together with other investigative apparatus including in fluids analysis and vitro tissue would help clinical decision-making. Mixed imaging techniques can provide supplementary information used to improve staging and therapy planning. Imaging aimed to find minimally invasive therapy to make better results and reduce side effects. Probably, the most important factor in reducing mortality of certain cancers is an early diagnosis of cancer via screening based on imaging. The most common cancer in women is breast cancer. It is considered as the second major cause of cancer deaths in females, and therefore it remained as an important medical and socio-economic issue. Medical imaging has always formed part of breast cancer care and has used in all phases of cancer management from detection and staging to therapy monitoring and post-therapeutic follow-up. An essential action to be performed in the preoperative staging of breast cancer based on breast imaging. The general term of breast imaging refers to breast sonography, mammography, and magnetic resonance tomography (MRT) of the breast (magnetic resonance mammography, MRM). Further development in technology will lead to increase imaging speed to meet physiological processes requirements. One of the issues in the diagnosis of breast cancer is sensitivity limitation. To overcome this limitation, complementary imaging examinations are utilised that traditionally includes screening ultrasound, and combined mammography and ultrasound. Development in targeted imaging and therapeutic agents calls for close cooperation among academic environment and industries such as biotechnological, IT and pharmaceutical industries.

Citing Articles

Monitoring concentration and lipid signature of plasma extracellular vesicles from HR metastatic breast cancer patients under CDK4/6 inhibitors treatment.

Richard M, Moreau R, Croyal M, Mathiot L, Frenel J, Campone M J Extracell Biol. 2024; 3(12):e70013.

PMID: 39691590 PMC: 11650302. DOI: 10.1002/jex2.70013.

Shear Wave Elastography in Breast Cancer: Unveiling Correlations With Histopathological Grades and Subtypes.

Asafu Adjaye Frimpong G, Aboagye E, Owusu-Afriyie O, Bonsu E, Mahama F, Asante E Cureus. 2024; 16(7):e63759.

PMID: 39099972 PMC: 11296557. DOI: 10.7759/cureus.63759.

Multivalent DNAzyme agents for cleaving folded RNA.

Dubovichenko M, Batsa M, Bobkov G, Vlasov G, El-Deeb A, Kolpashchikov D Nucleic Acids Res. 2024; 52(10):5866-5879.

PMID: 38661191 PMC: 11162777. DOI: 10.1093/nar/gkae295.

miR-125 in Breast Cancer Etiopathogenesis: An Emerging Role as a Biomarker in Differential Diagnosis, Regenerative Medicine, and the Challenges of Personalized Medicine.

Piergentili R, Marinelli E, Cucinella G, Lopez A, Napoletano G, Gullo G Noncoding RNA. 2024; 10(2).

PMID: 38525735 PMC: 10961778. DOI: 10.3390/ncrna10020016.

Cancer care at the time of the fourth industrial revolution: an insight to healthcare professionals' perspectives on cancer care and artificial intelligence.

Hesso I, Kayyali R, Dolton D, Joo K, Zacharias L, Charalambous A Radiat Oncol. 2023; 18(1):167.

PMID: 37814325 PMC: 10561443. DOI: 10.1186/s13014-023-02351-z.

References

Kruse S, Smith J, Lawrence A, Dresner M, Manduca A, Greenleaf J . Tissue characterization using magnetic resonance elastography: preliminary results. Phys Med Biol. 2000; 45(6):1579-90. DOI: 10.1088/0031-9155/45/6/313. View

Plewes D, Bishop J, Samani A, Sciarretta J . Visualization and quantification of breast cancer biomechanical properties with magnetic resonance elastography. Phys Med Biol. 2000; 45(6):1591-610. DOI: 10.1088/0031-9155/45/6/314. View

Sinkus R, Lorenzen J, Schrader D, Lorenzen M, Dargatz M, Holz D . High-resolution tensor MR elastography for breast tumour detection. Phys Med Biol. 2000; 45(6):1649-64. DOI: 10.1088/0031-9155/45/6/317. View

Kurhanewicz J, Vigneron D, Nelson S . Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia. 2000; 2(1-2):166-89. PMC: 1531872. DOI: 10.1038/sj.neo.7900081. View

Leach M . Application of magnetic resonance imaging to angiogenesis in breast cancer. Breast Cancer Res. 2001; 3(1):22-7. PMC: 138673. DOI: 10.1186/bcr266. View

Nunes L . Architectural-based interpretations of breast MR imaging. Magn Reson Imaging Clin N Am. 2001; 9(2):303-20, vi. View

Zhao M, Beauregard D, Loizou L, Davletov B, Brindle K . Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001; 7(11):1241-4. DOI: 10.1038/nm1101-1241. View

McKnight A, Kugel J, Rossman P, Manduca A, Hartmann L, Ehman R . MR elastography of breast cancer: preliminary results. AJR Am J Roentgenol. 2002; 178(6):1411-7. DOI: 10.2214/ajr.178.6.1781411. View

Beyer T, Townsend D, Blodgett T . Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med. 2002; 46(1):24-34. View

10.

Kolb T, Lichy J, Newhouse J . Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002; 225(1):165-75. DOI: 10.1148/radiol.2251011667. View

11.

Yeung D, Yang W, Tse G . Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology. 2002; 225(1):190-7. DOI: 10.1148/radiol.2243011519. View

12.

Artemov D, Mori N, Okollie B, Bhujwalla Z . MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003; 49(3):403-8. DOI: 10.1002/mrm.10406. View

13.

Smith J, Sorensen A, Thrall J . Biomarkers in imaging: realizing radiology's future. Radiology. 2003; 227(3):633-8. DOI: 10.1148/radiol.2273020518. View

14.

Jong R, Yaffe M, Skarpathiotakis M, Shumak R, Danjoux N, Gunesekara A . Contrast-enhanced digital mammography: initial clinical experience. Radiology. 2003; 228(3):842-50. DOI: 10.1148/radiol.2283020961. View

15.

Lewin J, Isaacs P, Vance V, Larke F . Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Radiology. 2003; 229(1):261-8. DOI: 10.1148/radiol.2291021276. View

16.

Coover L, Caravaglia G, Kuhn P . Scintimammography with dedicated breast camera detects and localizes occult carcinoma. J Nucl Med. 2004; 45(4):553-8. View

17.

Poplack S, Paulsen K, Hartov A, Meaney P, Pogue B, Tosteson T . Electromagnetic breast imaging: average tissue property values in women with negative clinical findings. Radiology. 2004; 231(2):571-80. DOI: 10.1148/radiol.2312030606. View

18.

Brindle K . Molecular imaging using magnetic resonance: new tools for the development of tumour therapy. Br J Radiol. 2004; 76 Spec No 2:S111-7. DOI: 10.1259/bjr/50577981. View

19.

Papantoniou V, Tsiouris S, Mainta E, Valotassiou V, Souvatzoglou M, Sotiropoulou M . Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography. Breast Cancer Res. 2005; 7(1):R33-45. PMC: 1064097. DOI: 10.1186/bcr948. View

20.

Rhodes D, OConnor M, Phillips S, Smith R, Collins D . Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast. Mayo Clin Proc. 2005; 80(1):24-30. DOI: 10.1016/S0025-6196(11)62953-4. View